首页|Radiation Oncology Unit Reports Findings in Artificial Intelligence (Efficacy of stereotactic body radiotherapy and response prediction using artificial intelligence in oligometastatic gynaecologic cancer)
Radiation Oncology Unit Reports Findings in Artificial Intelligence (Efficacy of stereotactic body radiotherapy and response prediction using artificial intelligence in oligometastatic gynaecologic cancer)
扫码查看
点击上方二维码区域，可以放大扫码查看
原文链接
NETL
NSTL
New research on Artificial Intelligence is the subject of a report. According to news reporting originating in Campobasso, Italy, by NewsRx journalists, research stated, “We present a large real-world multicentric dataset of ovarian, uterine and cervical oligometastatic lesions treated with SBRT exploring efficacy and clinical outcomes. In addition, an exploratory machine learning analysis was performed.” The news reporters obtained a quote from the research from Radiation Oncology Unit, “A pooled analysis of gynecological oligometastases in terms of efficacy and clinical outcomes as well an exploratory machine learning model to predict the CR to SBRT were carried out. The CR rate following radiotherapy (RT) was the study main endpoint. The secondary endpoints included the 2-year actuarial LC, DMFS, PFS, and OS. 501 patients from 21 radiation oncology institutions with 846 gynecological metastases were analyzed, mainly ovarian (53.1%) and uterine metastases(32.1%).Multiple fraction radiotherapy was used in 762 metastases(90.1%).The most frequent schedule was 24 Gy in 3 fractions(13.4%). CR was observed in 538(63.7%) lesions. The Machine learning analysis showed a poor ability to find covariates strong enough to predict CR in the whole series. Analyzing them separately, in uterine cancer, if RT dose 78.3Gy, the CR probability was 75.4%; if volume was ＜13.7 cc, the CR probability became 85.1%. In ovarian cancer, if the lesion was a lymph node, the CR probability was 71.4%; if volume was ＜17 cc, the CR probability rose to 78.4%. No covariate predicted the CR for cervical lesions. The overall 2-year actuarial LC was 79.2%, however it was 91.5% for CR and 52.5% for not CR lesions(p ＜0.001). The overall 2-year DMFS, PFS and OS rate were 27.3%, 24.8% and 71.0%, with significant differences between CR and not CR. CR was substantially associated to patient outcomes in our series of gynecological cancer oligometastatic lesions.” According to the news reporters, the research concluded: “The ability to predict a CR through artificial intelligence could also drive treatment choices in the context of personalized oncology.”
CampobassoItalyEuropeArtificial IntelligenceCancerCyborgsDrugs and TherapiesEmerging TechnologiesGynecologyHealth and MedicineMachine LearningOncologyRadiotherapyWomen’s Health
NETL
NSTL
